Expression of caspase-3 and the cytokine level in experimental reperfusion syndrome upon treatment with peroxiredoxin 6


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Ischemia-reperfusion injury is a significant problem; there is a need for interpretation of its pathogenetic mechanism and a search for potential methods of correction. The aim of this study was to investigate the cytokine content and the proapoptotic protein expression, including caspase-3, in experimental ischemia–reperfusion injury, and to assess the effectiveness of peroxiredoxin 6 treatment. Studies were conducted on 56 white male Wistar line rats weighing 180–200 g, in which ischemia–reperfusion injury was simulated by cross clamping both hind limbs. Proinflammatory cytokines in blood serum, the expression of caspase-3 in the cells of blood vessels, lungs, and kidneys were analyzed after ischemia–reperfusion injury and upon the peroxiredoxin 6 preventive treatment. It was found that the progression of ischemia–reperfusion injury is followed by proinflammatory cytokine activation in the rat blood: the maximum values of interleukin 1β, which were almost 10 times higher than the control, have been observed by 12 h of reperfusion. Ischemia–reperfusion injury was accompanied by an caspase-3 increase in the cells of rat limb vessels and the lungs after 6 h of reperfusion. Peroxiredoxin 6 treatment neutralizes oxidative stress primarily in the limb blood vessels, reducing the degree of vessel tissue destruction in the hind limbs that should be considered as a target for therapy of ischemia–reperfusion injury.

About the authors

A. V. Kubyshkin

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

S. V. Novosyolov

Institute of Cell Biophysics

Author for correspondence.
Email: novoselov-vi@rambler.ru
Russian Federation, Pushchino, Moscow oblast, 142290

I. I. Fomochkina

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

V. Z. Kharchenko

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

A. A. Pisarev

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

A. E. Gordeeva

Institute of Cell Biophysics

Email: novoselov-vi@rambler.ru
Russian Federation, Pushchino, Moscow oblast, 142290

A. A. Beketov

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

A. V. Kochkina

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

M. I. Fedosov

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

L. V. Anisimova

Medical Academy named after S.I. Georgievsky

Email: novoselov-vi@rambler.ru
Russian Federation, Simferopol, Republic of Crimea, 295051

R. G. Goncharov

Institute of Cell Biophysics

Email: novoselov-vi@rambler.ru
Russian Federation, Pushchino, Moscow oblast, 142290

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Pleiades Publishing, Inc.